Management of disseminated kidney cancer.
The approach to disseminate renal cell carcinoma (RCC) has evolved significantly in recent years, largely owing to the progress of biologic therapy development. With increasing knowledge of biologic therapy come several dilemmas, including the choice of cytokine therapy, the appropriate mode of delivery, the selection of candidates for given therapeutic options, and the role of cytoreductive nephrectomy in immunotherapy protocols. This article reviews the historical development of immunotherapy and the lessons learned from previous experience and offers a logical approach to the patient with disseminated RCC.
Taneja
S S
SS
Division of Urology, University of California, Los Angeles School of Medicine.
Pierce
W
W
Figlin
R
R
Belldegrun
A
A
D002292:Carcinoma, Renal Cell / Q000556:secondary* / Q000628:therapy*; D003131:Combined Modality Therapy; D006801:Humans; D007167:Immunotherapy; D007680:Kidney Neoplasms / Q000473:pathology* / Q000628:therapy; D009392:Nephrectomy